# AbbVie (ABBV) Forecast Calculator

Interactive five-year financial forecast and DCF for AbbVie. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/abbvie/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 33266000000 | 12772000000 | 13447000000 | 7882000000 |
| 2022 | 45804000000 | 16790000000 | 12029000000 | 4616000000 |
| 2023 | 56197000000 | 21990000000 | 18727000000 | 11542000000 |
| 2024 | 58054000000 | 24248000000 | 18895000000 | 11836000000 |
| 2025 | 54318000000 | 22062000000 | 13509000000 | 4863000000 |

## Frequently asked questions

### What kind of company is AbbVie and what are its main business areas?

AbbVie is a global, research-based biopharmaceutical company focused on discovering and delivering innovative medicines and aesthetic products. Its primary business segments include Immunology, Neuroscience, Aesthetics, and Oncology, driven by a portfolio of key products and recent acquisitions.

### What are the key revenue drivers for AbbVie, especially considering recent market changes?

AbbVie's revenue is primarily driven by its immunology portfolio, including Skyrizi and Rinvoq, along with products in Neuroscience, Aesthetics, and Oncology. The rapid growth of newer immunology assets and recent acquisitions are crucial for offsetting revenue erosion from the Humira loss of exclusivity.

### What is a key assumption regarding capital expenditure in the AbbVie financial model?

The financial model assumes a very low capital expenditure as a percentage of revenue, typically ranging from 1.5% to 2.0%. This reflects AbbVie's asset-light physical manufacturing model, with maintenance capex and biologic manufacturing capacity expansion being the main components.

### What is the primary goal of the financial model for AbbVie's valuation?

The financial model's primary goal is to evaluate AbbVie's sum-of-the-parts revenue trajectory and cash flow generation. This analysis ultimately informs an equity valuation and an assessment of the company's dividend sustainability.

### What is the forecast horizon for the downloadable AbbVie financial model?

The downloadable Excel financial model for AbbVie provides a forecast horizon spanning from Fiscal Year 2026 through Fiscal Year 2030. This model is designed to analyze the company's future financial performance and cash flow generation.

### How does AbbVie's business model address the challenge of patent expirations for its blockbuster drugs?

AbbVie's business model is highly reliant on continuous research and development and strategic acquisitions to replenish its pipeline. This strategy, exemplified by major deals like Allergan and ImmunoGen, aims to introduce new innovative medicines and offset revenue erosion from legacy blockbusters like Humira facing biosimilar competition.